SCHEMBL30765892

SCHEMBL30765892

CCCCOC(=O)Cn1ccnc(Cl)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
CNR1 P21554 1/20 0.44
L3MBTL1 Q9Y468 4/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
POLB P06746 2/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 2/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALOX15 P16050 1/20 0.38
PSMD14 O00487 1/20 0.38
APAF1 O14727 1/20 0.38
USP2 O75604 1/20 0.38
HSP90AA1 P07900 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12636575 0.86 FPR2 (0.46) LMNAMEN1KMT2AALDH1A1POLB
SCHEMBL21539717 0.80 LMNA (0.45) LMNAMEN1KMT2ACNR1L3MBTL1
SCHEMBL23885502 0.79 LMNA (0.45) LMNAMEN1KMT2ACNR1L3MBTL1
SCHEMBL27947806 0.76 LMNA (0.50) LMNAMEN1KMT2AALDH1A1TDP1
SCHEMBL22356899 0.74 LMNA (0.41) LMNAMEN1KMT2ACNR1L3MBTL1
SCHEMBL23885633 0.74 LMNA (0.45) LMNAMEN1KMT2ACNR1L3MBTL1
SCHEMBL30254395 0.74 LMNA (0.45) LMNAMEN1KMT2ACNR1L3MBTL1
SCHEMBL11250299 0.72 KMT2A (0.36) LMNAKMT2AL3MBTL1GAAALDH1A1
SCHEMBL30254206 0.72 P2RX7 (0.53) LMNAMEN1KMT2ACNR1TSHR
SCHEMBL12636573 0.71 FPR2 (0.46) LMNAMEN1KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed